Home › Companies › Supernus Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 18, 2026: 5 items on Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Supernus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Supernus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Frederick M. Hudson | 45,058,634 | -- | -- | 2,177,068 | 3,073,181 | 95% | Not verified | — |
| Elect Director: Charles W. Newhall, III | 41,743,154 | -- | -- | 5,492,548 | 3,073,181 | 88% | Not verified | — |
| 2. To approve, on a non-binding basis, the compensation paid to our named executive officers | 45,552,633 | 1,675,355 | 7,714 | -- | 3,073,181 | 96% | Not verified | — |
| 3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026 | 49,882,228 | 417,336 | 9,319 | -- | 0 | 99.1% | Not verified | — |
| 4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc | 41,925,692 | 5,302,088 | 7,922 | -- | 3,073,181 | 89% | Not verified | — |
Source: Supernus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
Each item below shows how the 372 asset managers that disclosed a Supernus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Charles W. Newhall, III
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Charles W. Newhall, III”): 41,743,154 for, 5,492,548 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 105 asset managers below reported 22,147,845 for, 1,753,571 withheld, 45 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,583,059 | 0 | 45 | 9,800 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 3,716 | 0 | 0 | 998,212 | Withhold |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 207,993 | Withhold |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 172,113 | 0 | 0 | 13,307 | Mixed |
| Lincoln Financial | 136,521 | 0 | 0 | 40,087 | Mixed |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 131,115 | Withhold |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 77,744 | 0 | 0 | 32,300 | Mixed |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Frederick M. Hudson
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Frederick M. Hudson”): 45,058,634 for, 2,177,068 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 104 asset managers below reported 23,492,373 for, 403,638 withheld, 16 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,583,088 | 0 | 16 | 9,800 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,850 | 0 | 0 | 78 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 172,113 | 0 | 0 | 13,307 | Mixed |
| Lincoln Financial | 172,911 | 0 | 0 | 3,697 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 131,115 | Withhold |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 77,744 | 0 | 0 | 32,300 | Mixed |
Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.
Combines 2 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: TO CONSIDER AND ACT UPON A PROPOSAL TO AMEND THE SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE UNDER THE PLAN.
Supernus Pharmaceuticals, Inc.’s own tally for this item (“4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 41,925,692 for, 5,302,088 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 108 asset managers below reported 21,906,605 for, 1,946,172 against, 3,810 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,575,557 | 17,346 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 2,338 | 999,590 | 0 | 0 | Against |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 0 | 312,681 | 0 | 0 | Against |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 186,124 | 21,276 | 0 | 0 | Mixed |
| Brighthouse | 181,610 | 0 | 3,810 | 0 | For |
| Lincoln Financial | 140,218 | 36,390 | 0 | 0 | Mixed |
| World Funds Trust | 0 | 167,126 | 0 | 0 | Against |
| American Century | 0 | 159,445 | 0 | 0 | Against |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 0 | 152,349 | 0 | 0 | Against |
| JPMorgan | 131,115 | 0 | 0 | 0 | For |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Empower | 118,324 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 110,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 108 asset managers. See all 108 in the interactive database.
Combines 8 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding basis, the compensation paid to our named executive officers.
Supernus Pharmaceuticals, Inc.’s own tally for this item (“2. To approve, on a non-binding basis, the compensation paid to our named executive officers”): 45,552,633 for, 1,675,355 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Supernus Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” (2 managers, 52 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,592,891 | 12 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,928 | 0 | 0 | 0 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 172,113 | 9,497 | 3,810 | 0 | Mixed |
| Lincoln Financial | 172,911 | 3,697 | 0 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 0 | 159,445 | 0 | 0 | Against |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 131,115 | 0 | 0 | Against |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Empower | 118,324 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 110,044 | 0 | 0 | 0 | For |
Fund voting reports, all 106 managers: 23,348,090 for, 507,676 against, 3,810 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 2,395,465 | 878 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,829,285 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,533,481 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,489,631 | 0 | 0 | 0 | For |
| Loomis Sayles | 1,248,354 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,168,784 | 0 | 0 | 0 | For |
| State Street | 1,137,426 | 0 | 0 | 0 | For |
| Renaissance | 1,108,266 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 21,276 | 0 | 0 | 0 | For |
| Citadel | 861,525 | 0 | 0 | 0 | For |
| Charles Schwab | 708,058 | 0 | 0 | 0 | For |
| Northern Trust | 590,556 | 0 | 0 | 0 | For |
| ASHFORD CAPITAL MANAGEMENT INC | 570,444 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 568,124 | 0 | 0 | 0 | For |
| Vanguard | 467,650 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 454,625 | 0 | 0 | 0 | For |
| Victory Capital | 407,806 | 0 | 0 | 0 | For |
| Woodline Partners LP | 407,024 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 402,454 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 341,601 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 338,223 | 0 | 0 | 0 | For |
| Freestone Grove Partners LP | 275,956 | 0 | 0 | 0 | For |
| MetLife Investment Management, LLC | 261,601 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 254,546 | 0 | 0 | Against |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 229,712 | 1,855 | 0 | 0 | For |
Institutional-manager reports, all 289 managers: 24,321,889 for, 807,866 against, 359 not voted, 877,834 mixed. Showing the 25 largest; see all in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Supernus Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026”): 49,882,228 for, 417,336 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 105 asset managers below reported 23,897,570 for, 81 against, 3,810 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,592,900 | 3 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,850 | 78 | 0 | 0 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| Brighthouse | 181,610 | 0 | 3,810 | 0 | For |
| Lincoln Financial | 176,608 | 0 | 0 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 131,115 | 0 | 0 | 0 | For |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
| Equitable | 110,044 | 0 | 0 | 0 | For |
Showing the 25 largest of 105 asset managers. See all 105 in the interactive database.
Not shown here: this season’s fund filings also report 4 items from the meeting of June 16, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,039,721 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.36% |
| 2 | BlackRock | 10.54% |
| 3 | Fidelity | 2.64% |
| 4 | Delaware/Macquarie | 2.50% |
| 5 | State Street | 1.73% |
| 6 | Dimensional | 1.13% |
| 7 | Charles Schwab | 1.10% |
| 8 | Loomis Sayles | 0.92% |
| 9 | Invesco | 0.58% |
| 10 | AMG FUNDS | 0.54% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 4.13% |
| 2 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 3.15% |
| 3 | ARMISTICE CAPITAL, LLC | 2.64% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.57% |
| 5 | Loomis Sayles | 2.15% |
| 6 | Stephens Investment Management Group LLC | 2.01% |
| 7 | State Street | 1.96% |
| 8 | Renaissance | 1.91% |
| 9 | GW&K Investment Management, LLC | 1.55% |
| 10 | Citadel | 1.48% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 15.16% | 13F |
| BlackRock, Inc. and its affiliates | 14.12% | DEF14A |
| Vanguard Group | 10.42% | 13F |
| Jack A. Khattar + | 6.78% | DEF14A |
| Millennium Management | 5.71% | 13F |
| Millenium Management LLC and its affiliates | 5.65% | DEF14A |
| Vanguard Portfolio Management | 5.62% | 13G |
| Armistice Capital, LLC | 4.76% | DEF14A |
| Dimensional Fund Advisors LP | 4.67% | DEF14A |
| State Street | 3.94% | 13F |
Percentages above are of 58,039,721 shares outstanding, as reported by Supernus Pharmaceuticals, Inc. on its Form 10-Q dated April 28, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Supernus Pharmaceuticals, Inc.’s 10-Q dated April 28, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At Supernus Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 372 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,305 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding basis, the compensation paid to our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Supernus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Supernus Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.